# Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

> **NCT00144612** · PHASE3 · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 60 (actual)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** MRA(Tocilizumab)

## Key facts

- **NCT ID:** NCT00144612
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-06
- **Final completion:** 2009-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2009-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144612, "Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00144612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*